Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02432274 · OUTCOME

Cohorts 1, 2A, 2B, 3A and 3B: Time to Progression (TTP)

Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma · Source last updated 2023-07-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
From first dose of study drug until PD (Cohort 1, Cohort 2A, Cohort 2B: until the data cut-off date, 31 May 2019; Cohort 3A, Cohort 3B: until the data cut-off date, 18 July 2019)

What was measured

TTP was defined as the time from the date of first dose of study drug to the date of first documentation of PD based on RECIST 1.1. PD was defined as at least a 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the baseline SOD of target lesions. 95% CI of median were calculated according to Brookmeyer and Crowley method.

Analysis population: Full analysis set included all enrolled participants who did not fail study screening.

Groups in this outcome

Cohort 1, Single-agent Dose-finding: Lenvatinib 11 mg/m^2

Participants (age group 2 to \<6 years \[following completion of run-in period\] and 6 to \<18 years) with relapsed or refractory solid malignant tumors received lenvatinib 11 mg/m\^2 (per BSA, daily dose capped at 24 mg/day) as capsules or suspension (lenvatinib capsules were dissolved in water or apple juice for participants who were unable to swallow capsules and given as suspension), orally, once daily on Days 1 to 28 of each treatment cycle as single agent until PD, intolerable toxicity, participant noncompliance with safety or efficacy assessments, initiation of another anticancer therapy, voluntary discontinuation by participant at any time, or study termination by sponsor, whichever occurred first. Duration of each treatment cycle in Cohort 1=28 days.

Cohort 1, Single-agent Dose-finding: Lenvatinib 14 mg/m^2

Participants (age group 2 to \<6 years \[following completion of run-in period\] and 6 to \<18 years) with relapsed or refractory solid malignant tumors received lenvatinib 14 mg/m\^2 (per BSA, daily dose capped at 24 mg/day) as capsules or suspension (lenvatinib capsules were dissolved in water or apple juice for participants who were unable to swallow capsules and given as suspension), orally, once daily on Days 1 to 28 of each treatment cycle as a single agent until PD, intolerable toxicity, participant noncompliance with safety or efficacy assessments, initiation of another anticancer therapy, voluntary discontinuation by participant at any time, or study termination by sponsor, whichever occurred first. Duration of each treatment cycle in Cohort 1=28 days.

Cohort 1, Single-agent Dose-finding: Lenvatinib 17 mg/m^2

Participants (of age group 6 to \<18 years) with relapsed or refractory solid malignant tumors received dose of lenvatinib 17 mg/m\^2 (administered per BSA, daily dose capped at 24 mg/day) as capsules or suspension (lenvatinib capsules were dissolved in water or apple juice for participants who were unable to swallow capsules and given as suspension), orally, once daily on Days 1 to 28 of each treatment cycle as a single agent until PD, intolerable toxicity, participant noncompliance with safety or efficacy assessments, initiation of another anticancer therapy, voluntary discontinuation by the participant at any time, or study termination by the sponsor, whichever occurred first. Duration of each treatment cycle in Cohort 1=28 days.

Cohort 2A, Single-agent Expansion, DTC: Lenvatinib 14 mg/m^2

Participants with 131 iodine-refractory DTC received lenvatinib 14 mg/m\^2 (administered per BSA with daily dose capped at 24 mg/day) as capsules or suspension (lenvatinib capsules were dissolved in water or apple juice for participants who were unable to swallow capsules and given as suspension), orally, once daily on Days 1 to 28 of each treatment cycle as a single agent until PD, intolerable toxicity, participant noncompliance with safety or efficacy assessments, initiation of another anticancer therapy, voluntary discontinuation by the participant at any time, or study termination by the sponsor, whichever occurred first. Duration of each treatment cycle in Cohort 2A=28 days.

Cohort2B,Single-agentExpansion,Osteosarcoma:Lenvatinib14mg/m^2

Participants with relapsed or refractory osteosarcoma received lenvatinib 14 mg/m\^2 (administered per BSA with daily dose capped at 24 mg/day) as capsule or suspension (lenvatinib capsules were dissolved in water or apple juice for participants who were unable to swallow capsules and given as suspension), orally, once daily on Days 1 to 28 of each treatment cycle as a single agent until PD, intolerable toxicity, participant noncompliance with safety or efficacy assessments, initiation of another anticancer therapy, voluntary discontinuation by the participant at any time, or study termination by the sponsor, whichever occurred first. Duration of each treatment cycle in Cohort 2B=28 days.

Cohort 3A, Combination Dose-finding: Lenvatinib 11 mg/m^2

Participants with relapsed or refractory osteosarcoma received lenvatinib 11 mg/m\^2 (20% lower than the RD from Cohort 1; administered per BSA with daily dose capped at 24 mg/day) as capsules or suspension (lenvatinib capsules were dissolved in water or apple juice for participants who were unable to swallow capsules and given as suspension), orally, once daily on Days 1 to 21 of each treatment cycle in combination with ifosfamide 3000 mg/m\^2/day intravenously and etoposide 100 mg/m\^2/day intravenously on Days 1 to 3 of each treatment cycle for up to a total of 5 cycles as a combination therapy. Duration of each treatment cycle in Cohort 3A=21 days.

Cohort 3A, Combination Dose-finding: Lenvatinib 14 mg/m^2

Participants with relapsed or refractory osteosarcoma received lenvatinib 14 mg/m\^2 (administrated per BSA with daily dose capped at 24 mg/day) as capsules or suspension (lenvatinib capsules were dissolved in water or apple juice for participants who were unable to swallow capsules and given as suspension), orally, once daily on Days 1 to 21 of each treatment cycle in combination with ifosfamide 3000 mg/m\^2/day intravenously and etoposide 100 mg/m\^2/day intravenously on Days 1 to 3 of each treatment cycle for up to a total of 5 cycles as a combination therapy. Duration of each treatment cycle in Cohort 3A=21 days.

Cohort 3B, Combination Expansion: Lenvatinib 14 mg/m^2

Participants with relapsed or refractory osteosarcoma received lenvatinib 14 mg/m\^2 (administrated per BSA with daily dose capped at 24 mg/day) as capsules or suspension (lenvatinib capsules were dissolved in water or apple juice for participants who were unable to swallow capsules and given as suspension), orally, once daily on Days 1 to 21 of each treatment cycle in combination with ifosfamide 3000 mg/m\^2/day intravenously and etoposide 100 mg/m\^2/day intravenously on Days 1 to 3 of each treatment cycle for up to a total of 5 cycles as a combination therapy. Duration of each treatment cycle in Cohort 3B=21 days.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cohort 1, Single-agent Dose-finding: Lenvatinib 11 mg/m^23
Cohort 1, Single-agent Dose-finding: Lenvatinib 14 mg/m^29
Cohort 1, Single-agent Dose-finding: Lenvatinib 17 mg/m^211
Cohort 2A, Single-agent Expansion, DTC: Lenvatinib 14 mg/m^21
Cohort2B,Single-agentExpansion,Osteosarcoma:Lenvatinib14mg/m^231
Cohort 3A, Combination Dose-finding: Lenvatinib 11 mg/m^27
Cohort 3A, Combination Dose-finding: Lenvatinib 14 mg/m^215
Cohort 3B, Combination Expansion: Lenvatinib 14 mg/m^220

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Cohort 1, Single-agent Dose-finding: Lenvatinib 11 mg/m^23.7Not reported0.55.0Not reported
Cohort 1, Single-agent Dose-finding: Lenvatinib 14 mg/m^26.3Not reported0.610.6Not reported
Cohort 1, Single-agent Dose-finding: Lenvatinib 17 mg/m^25.5Not reported1.411.3Not reported
Cohort 2A, Single-agent Expansion, DTC: Lenvatinib 14 mg/m^25.5Not reportedNANA95% CI could not be estimated as insufficient number of participants were available for analysis.
Cohort2B,Single-agentExpansion,Osteosarcoma:Lenvatinib14mg/m^23.0Not reported1.85.4Not reported
Cohort 3A, Combination Dose-finding: Lenvatinib 11 mg/m^27.1Not reported2.1NAUpper limit of 95% CI could not be estimated because high number of participants were censored from the analysis.
Cohort 3A, Combination Dose-finding: Lenvatinib 14 mg/m^212.0Not reported11.116.1Not reported
Cohort 3B, Combination Expansion: Lenvatinib 14 mg/m^26.9Not reported4.2NAUpper limit of 95% CI could not be estimated because high number of participants were censored from the analysis.
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.5
        upper Limit
        5.0
        value
        3.7
      2. group Id
        OG001
        lower Limit
        0.6
        upper Limit
        10.6
        value
        6.3
      3. group Id
        OG002
        lower Limit
        1.4
        upper Limit
        11.3
        value
        5.5
      4. comment
        95% CI could not be estimated as insufficient number of participants were available for analysis.
        group Id
        OG003
        lower Limit
        NA
        upper Limit
        NA
        value
        5.5
      5. group Id
        OG004
        lower Limit
        1.8
        upper Limit
        5.4
        value
        3.0
      6. comment
        Upper limit of 95% CI could not be estimated because high number of participants were censored from the analysis.
        group Id
        OG005
        lower Limit
        2.1
        upper Limit
        NA
        value
        7.1
      7. group Id
        OG006
        lower Limit
        11.1
        upper Limit
        16.1
        value
        12.0
      8. comment
        Upper limit of 95% CI could not be estimated because high number of participants were censored from the analysis.
        group Id
        OG007
        lower Limit
        4.2
        upper Limit
        NA
        value
        6.9
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    2. group Id
      OG001
      value
      9
    3. group Id
      OG002
      value
      11
    4. group Id
      OG003
      value
      1
    5. group Id
      OG004
      value
      31
    6. group Id
      OG005
      value
      7
    7. group Id
      OG006
      value
      15
    8. group Id
      OG007
      value
      20
    units
    Participants
description
TTP was defined as the time from the date of first dose of study drug to the date of first documentation of PD based on RECIST 1.1. PD was defined as at least a 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the baseline SOD of target lesions. 95% CI of median were calculated according to Brookmeyer and Crowley method.
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants (age group 2 to \<6 years \[following completion of run-in period\] and 6 to \<18 years) with relapsed or refractory solid malignant tumors received lenvatinib 11 mg/m\^2 (per BSA, daily dose capped at 24 mg/day) as capsules or suspension (lenvatinib capsules were dissolved in water or apple juice for participants who were unable to swallow capsules and given as suspension), orally, once daily on Days 1 to 28 of each treatment cycle as single agent until PD, intolerable toxicity, participant noncompliance with safety or efficacy assessments, initiation of another anticancer therapy, voluntary discontinuation by participant at any time, or study termination by sponsor, whichever occurred first. Duration of each treatment cycle in Cohort 1=28 days.
    id
    OG000
    title
    Cohort 1, Single-agent Dose-finding: Lenvatinib 11 mg/m^2
  2. description
    Participants (age group 2 to \<6 years \[following completion of run-in period\] and 6 to \<18 years) with relapsed or refractory solid malignant tumors received lenvatinib 14 mg/m\^2 (per BSA, daily dose capped at 24 mg/day) as capsules or suspension (lenvatinib capsules were dissolved in water or apple juice for participants who were unable to swallow capsules and given as suspension), orally, once daily on Days 1 to 28 of each treatment cycle as a single agent until PD, intolerable toxicity, participant noncompliance with safety or efficacy assessments, initiation of another anticancer therapy, voluntary discontinuation by participant at any time, or study termination by sponsor, whichever occurred first. Duration of each treatment cycle in Cohort 1=28 days.
    id
    OG001
    title
    Cohort 1, Single-agent Dose-finding: Lenvatinib 14 mg/m^2
  3. description
    Participants (of age group 6 to \<18 years) with relapsed or refractory solid malignant tumors received dose of lenvatinib 17 mg/m\^2 (administered per BSA, daily dose capped at 24 mg/day) as capsules or suspension (lenvatinib capsules were dissolved in water or apple juice for participants who were unable to swallow capsules and given as suspension), orally, once daily on Days 1 to 28 of each treatment cycle as a single agent until PD, intolerable toxicity, participant noncompliance with safety or efficacy assessments, initiation of another anticancer therapy, voluntary discontinuation by the participant at any time, or study termination by the sponsor, whichever occurred first. Duration of each treatment cycle in Cohort 1=28 days.
    id
    OG002
    title
    Cohort 1, Single-agent Dose-finding: Lenvatinib 17 mg/m^2
  4. description
    Participants with 131 iodine-refractory DTC received lenvatinib 14 mg/m\^2 (administered per BSA with daily dose capped at 24 mg/day) as capsules or suspension (lenvatinib capsules were dissolved in water or apple juice for participants who were unable to swallow capsules and given as suspension), orally, once daily on Days 1 to 28 of each treatment cycle as a single agent until PD, intolerable toxicity, participant noncompliance with safety or efficacy assessments, initiation of another anticancer therapy, voluntary discontinuation by the participant at any time, or study termination by the sponsor, whichever occurred first. Duration of each treatment cycle in Cohort 2A=28 days.
    id
    OG003
    title
    Cohort 2A, Single-agent Expansion, DTC: Lenvatinib 14 mg/m^2
  5. description
    Participants with relapsed or refractory osteosarcoma received lenvatinib 14 mg/m\^2 (administered per BSA with daily dose capped at 24 mg/day) as capsule or suspension (lenvatinib capsules were dissolved in water or apple juice for participants who were unable to swallow capsules and given as suspension), orally, once daily on Days 1 to 28 of each treatment cycle as a single agent until PD, intolerable toxicity, participant noncompliance with safety or efficacy assessments, initiation of another anticancer therapy, voluntary discontinuation by the participant at any time, or study termination by the sponsor, whichever occurred first. Duration of each treatment cycle in Cohort 2B=28 days.
    id
    OG004
    title
    Cohort2B,Single-agentExpansion,Osteosarcoma:Lenvatinib14mg/m^2
  6. description
    Participants with relapsed or refractory osteosarcoma received lenvatinib 11 mg/m\^2 (20% lower than the RD from Cohort 1; administered per BSA with daily dose capped at 24 mg/day) as capsules or suspension (lenvatinib capsules were dissolved in water or apple juice for participants who were unable to swallow capsules and given as suspension), orally, once daily on Days 1 to 21 of each treatment cycle in combination with ifosfamide 3000 mg/m\^2/day intravenously and etoposide 100 mg/m\^2/day intravenously on Days 1 to 3 of each treatment cycle for up to a total of 5 cycles as a combination therapy. Duration of each treatment cycle in Cohort 3A=21 days.
    id
    OG005
    title
    Cohort 3A, Combination Dose-finding: Lenvatinib 11 mg/m^2
  7. description
    Participants with relapsed or refractory osteosarcoma received lenvatinib 14 mg/m\^2 (administrated per BSA with daily dose capped at 24 mg/day) as capsules or suspension (lenvatinib capsules were dissolved in water or apple juice for participants who were unable to swallow capsules and given as suspension), orally, once daily on Days 1 to 21 of each treatment cycle in combination with ifosfamide 3000 mg/m\^2/day intravenously and etoposide 100 mg/m\^2/day intravenously on Days 1 to 3 of each treatment cycle for up to a total of 5 cycles as a combination therapy. Duration of each treatment cycle in Cohort 3A=21 days.
    id
    OG006
    title
    Cohort 3A, Combination Dose-finding: Lenvatinib 14 mg/m^2
  8. description
    Participants with relapsed or refractory osteosarcoma received lenvatinib 14 mg/m\^2 (administrated per BSA with daily dose capped at 24 mg/day) as capsules or suspension (lenvatinib capsules were dissolved in water or apple juice for participants who were unable to swallow capsules and given as suspension), orally, once daily on Days 1 to 21 of each treatment cycle in combination with ifosfamide 3000 mg/m\^2/day intravenously and etoposide 100 mg/m\^2/day intravenously on Days 1 to 3 of each treatment cycle for up to a total of 5 cycles as a combination therapy. Duration of each treatment cycle in Cohort 3B=21 days.
    id
    OG007
    title
    Cohort 3B, Combination Expansion: Lenvatinib 14 mg/m^2
param Type
MEDIAN
population Description
Full analysis set included all enrolled participants who did not fail study screening.
reporting Status
POSTED
time Frame
From first dose of study drug until PD (Cohort 1, Cohort 2A, Cohort 2B: until the data cut-off date, 31 May 2019; Cohort 3A, Cohort 3B: until the data cut-off date, 18 July 2019)
title
Cohorts 1, 2A, 2B, 3A and 3B: Time to Progression (TTP)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice